| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.19 | 0.002 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.15 | 0.002 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.15 | 0.003 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.099 | 0.003 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | 0.099 | 0.003 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.097 | 0.003 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.093 | 0.003 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |